Today in Focus: CYTK, DGXX

Trading Services I Use in my Trading:

I have an amazing deal with Stock Analysis for Subscribers (100 redemptions available).

You can get 1 month free, then an exclusive discount on your first year:

Stock Analysis Pro (Annual)
• 1 month free
• Code: IRISHBORNINVESTOR20 (20% Off First Year)

Stock Analysis Unlimited (Annual)
• 1 month free
• Code: IRISHBORNINVESTOR50 (50% Off First Year)

This is limited to the first 100 people and for just 7 days. It will go fast!

You must use this special link to access the private offer (and add the discount code) - StockAnalysis Trial

I’ve been using Stock Analysis as a super affordable but reliable method of looking at New and Upcoming IPOs, Earnings Calendars and most notably KPIs (Key Performance Indicators). Stock Analysis allows you to view the KPIs for many companies with up to date metrics and segments that you can cross reference against Earnings Results. This is incredibly important when understanding what metrics move a stock.

Market Condition: Short term extended, Bullish market higher time frame, High Risk on New Positions

Commentary: No change from yesterday. Higher risk on new positions here. Looking at two names specifically. Prefer the Biotech.

Also have alerts on BLZE (Flip to Operating Profitability), VVX (V Strong Book to Bill) as secondary names I’m monitoring.

Caution on adding too much new risk here. Many of these names may be better delayed reactions.

In Play

CYTK:  Positive Phase 3 Data

Key Metrics CYTK: Industry Group: Biotechnology, Market Cap: 10.33B, Float: 119.34M, Short Interest: 12.47%, Days to Cover: 7.78, Sales Y/Y TTM: 376.56%, EPS Y/Y TTM: -23.80%, Earnings: May 05 AMC, Exchange: NASDAQ

Catalyst: Cytokinetics announced positive topline results from ACACIA-HCM, the pivotal Phase 3 trial of aficamten (MYQORZO) in symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM), an indication with zero approved therapies. Hit statistical significance at p<0.001. The clinical significance is amplified by the direct comparator failure.

Aficamten therefore becomes the first cardiac myosin inhibitor and first therapy of any class to demonstrate efficacy in nHCM, an indication encompassing approximately half of the ~300,000 diagnosed U.S. HCM patients.

Nice Weekly chart. Strong institutional support with my sentiment research looking good. Buyout candidate. Meaningful Short Interest.

DGXX:  MSA with Cerebras Systems for AI Datacenter

Key Metrics DGXX: Industry Group: Utilities - Independent Power Producers, Market Cap: 496.11M, Float: 59.38M, Short Interest: 5.68%, Days to Cover: 1.64, Sales Y/Y TTM: -26.04%, EPS Y/Y TTM: 36.12%, Earnings: Mar 31 AMC, Exchange: NASDAQ

Catalyst: The 10-year initial term is valued at $1.1 billion, with total potential contract value of up to $2.5 billion inclusive of renewal terms. Development proceeds in two phases: Phase 1 (15 MW, targeted RFS December 15, 2026) and Phase 2 (25 MW, targeted Q1 2027). Substation construction is completed; Alabama Power interconnection is finalized. Phase 1 is described as self-funded.

Noting this one mainly with the connection to Cerebras which is soon to IPO and will be a hot name in AI Compute. The weakness is there is no money upfront meaning we could see the company dilute into this but monitoring nonetheless.

Current Positions: RVMD, TWLO, TH, DELL, BAND, BE, SBUX, GOOG, SWBI, MRAM, NVDA

Delayed Reaction Watchlist (TradingView Link)

_{Note: This is my methodology for identifying stocks in play. There are many valid approaches to trading catalysts—find the setups, timeframes, and risk parameters that align with your strategy.}